This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Organizational Changes Strengthen And Expand Celgene Leadership Team

Celgene Corporation (NASDAQ:CELG) today announced organizational changes that will go into effect on August 1, 2014.
  • Mark Alles is promoted to President and Chief Operating Officer (COO)
  • Jacqualyn Fouse, PhD, is promoted to President Hematology & Oncology
  • Scott Smith is promoted to President Inflammation & Immunology (I&I)
  • Peter Kellogg to join Celgene as Executive Vice President, Chief Financial Officer (CFO)

“These changes strengthen and expand our leadership team and position us to best capitalize on the strategic and operational opportunities in the years ahead,” said Bob Hugin, Chairman and Chief Executive Officer. “Mark, Jackie and Scott are outstanding proven leaders and well-prepared for their new responsibilities. Our business and financial strategies will be further enhanced by the expertise and experience that Peter brings to our team.”

As President and COO, Mark will focus on enhancing Celgene’s operational excellence and continue to drive world-class performance across our functional capabilities. With multiple franchises and marketed products in a growing portfolio of therapeutic categories, we are in a strong position to further leverage our global infrastructure and core global operating competencies. Mark is transitioning from his current role as Head of our Hematology & Oncology franchise having previously held multiple positions of increasing responsibility over his ten years at Celgene.

During Jackie’s four years as Celgene’s CFO, she has played a leading role in the formulation of our business and financial strategies, in addition to ensuring the achievement of important corporate milestones. This promotion represents an exceptional opportunity to leverage Jackie’s strong leadership, significant business experience and strategic perspective to lead the Hematology & Oncology franchise to even higher levels of success.

Scott has led our I&I franchise since 2009 from its early development stages to the globally evolving franchise we have today. Scott and his team are delivering exceptional results, including clinical trial execution, regulatory success, and the build-out of a world-class franchise infrastructure supporting the global commercial launch of OTEZLA ®. Going forward, he also assumes an expanded role in strategic corporate initiatives.

Peter will join Celgene on July 1, 2014, and will become CFO effective August 1st. Peter will be responsible for core financial functions including Investor Relations, in addition to Corporate Strategy, Business Development and Alliance Management. He is an industry veteran having most recently served as CFO and Executive Vice President at Merck & Co, Inc. Prior to Merck, Peter was CFO and Executive Vice President of Finance at Biogen Idec Inc.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 0.00%
FB $99.75 0.00%
GOOG $682.74 0.00%
TSLA $147.99 0.00%
YHOO $27.05 0.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs